Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study – Alzamend Neuro (NASDAQ:ALZN)
[ad_1] Alzamend Neuro Inc ALZN submitted an investigational new drug application to the FDA for its immunotherapy candidate, ALZN002. The product candidate is designed to treat mild to moderate dementia of…
Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial – Axcella Health (NASDAQ:AXLA)
[ad_1] Axcella Therapeutics AXLA reported interim results from its ongoing global Phase 2b EMMPACT study of AXA1125 for nonalcoholic steatohepatitis (NASH). At 24 weeks, Axcella said all patients taking the high…
These Stocks Are On The Radar After Biogen-Eisai’s Surprising Alzheimer’s Trial Win – Biogen (NASDAQ:BIIB)
[ad_1] One of the most-watched Alzheimer’s therapies in the clinic, Biogen Inc BIIB–Eisai Limited’s ESALY experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months…
Thermo Fisher’s Oncomine Dx Test Is First FDA Approved NGS-Based Companion Diagnostic To Detect Thyroid Cancers – Thermo Fisher Scientific (NYSE:TMO)
[ad_1] by Vandana Singh, Benzinga Editor September 28, 2022 8:11 AM | 1 min read The FDA approved Thermo Fisher Scientific Inc’s TMO Oncomine Dx Target Test as a companion diagnostic (CDx)…
Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose – Eagle Pharmaceuticals (NASDAQ:EGRX)
[ad_1] Eagle Pharmaceuticals Inc EGRX announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (BARDA). In partnership with BARDA, ENA-001 is…